Earnings report for Aileron Therapeutics, Inc. (NASDAQ:ALRN) is expected on April, 1., RTT reports. The EPS diference is $0.03 or 6.38 % down from last years number. Previous year: $-0.47; Analysts forcast: $-0.50. Last quarter $-0.50 EPS was reported. Analysts sees 0.00 % EPS growth this quarter. Ticker’s shares touched $1.9353 during the last trading session after 0.80% change.Currently Aileron Therapeutics, Inc. is downtrending after 81.10% change in last March 15, 2018. ALRN has 18,379 shares volume. ALRN underperformed the S&P500 by 85.47%.

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing a novel class of therapeutics in the United States.The firm is worth $28.54 million. The company??s lead product includes ALRN-6924, a stapled peptide that in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial for the treatment of peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia and advanced myelodysplastic syndrome (MDS); and Phase II b trial for the treatment of AML/MDS in combination with cytosine arabinoside.Currently it has negative earnings. It is also developing next generation wild type p53 reactivator that is in preclinical stage for the treatment of solid and liquid tumors.

For more Aileron Therapeutics, Inc. (NASDAQ:ALRN) news published briefly go to: Nasdaq.com, Benzinga.com, Seekingalpha.com, Globenewswire.com or Seekingalpha.com. The titles are as follows: “Aileron Therapeutics, Inc. (ALRN) Upgraded to Strong Buy: Here’s Why – Nasdaq” published on January 29, 2019, “Benzinga’s Top Upgrades, Downgrades For March 11, 2019 – Benzinga” on March 11, 2019, “Aileron tries to right the ship; up 21% – Seeking Alpha” with a publish date: August 20, 2018, “Aileron Therapeutics Announces Changes to Management Nasdaq:ALRN – GlobeNewswire” and the last “Aileron up 35% on advancement of ALRN-6924 + Ibrance study – Seeking Alpha” with publication date: January 16, 2019.